DALLAS, June 18, 2015 /PRNewswire/ —
Global Heparin Market 2015-2019 research report says increased R&D investments for exploitation of novel therapeutic applications of heparin and strategic alliances encouraging growth prospects in the heparin sector for the next 4-5 years.
Complete report on heparin market spread across 80 pages, talking about 4 major companies and supported with 30 exhibits is now available at http://www.reportsnreports.com/reports/402194-global-heparin-market-2015-2019.html .
According to this heparin market 2015 research report, an increase in the incidence of acute coronary syndrome and macrovascular disease, leading to thrombosis, may have a positive impact on the market. The anti-inflammatory activity of heparin is a recent discovery. Heparin exhibits this trait through the neutralization of cationic mediators, inhibition of adhesion molecules, and the inhibition of heparanase, all of which are involved in leukocyte recruitment into tissues. Further studies are being conducted to exploit the use of heparin as an anti-inflammatory agent.
The growing prevalence of diseases is one of the key drivers of the heparin market. Diseases such as coronary heart disease, kidney disorders, stroke, and inflammatory conditions are a result of blood clots, leading to a rise in the demand for heparin drugs. Further, the report states that the patent expiry of top-selling drugs is a major challenge to vendors in the heparin market, leading to the entry of generic drugs in the market and, consequently, a reduction in the price of branded drugs.
Co-development agreements for different geographical segments enable the penetration of drugs into particular regions. To capture maximum market shares and expand the focus area, vendors are investing more in R&D. For instance, Pfizer and the Ontario Clinical Oncology Group conducted a joint study to identify the survival rates of patients with epithelial ovarian carcinoma when dalteparin is used.
Companies mentioned in this heparin market research include Aspen, Leo Pharma, Pfizer and Sanofi-Aventis. Other prominent players are Alchemia, Archimedes Pharma, Celgene, Dr. Reddy’s, Eisai, Laboratorios Rovi Pharmaceuticals, Lee’s Pharmaceutical, Menarini Group, Mylan, Sagent Pharmaceuticals, Fresenius Kabi, GlaxoSmithKline, Hospira, Sigma Tau and UCB. Order a copy of global heparin market 2015-2019 research report at http://www.reportsnreports.com/Purchase.aspx?name=402194 .
For reports by Technavio / Infiniti Research Limited, ReportsnReports.com is running a special offer wherein 3 reports can be purchased at the cost of 2 (lowest priced report will be free) or if the reports are of same price, pay for 2 and get the third report free. If you order 4 or more reports in a single order, you get 50% flat discount on the total pricing. To avail this offer, send an email to firstname.lastname@example.org with your market research reports requirements or call us on +1 888 391 5441 to avail this offer.
Key heparin market trends discussed in this research include expected Exploitation of new therapeutic use, increase in R&D, strategic alliances and entry of new heparin antidotes. Market drivers like growing prevalence of diseases, increase in supply of crude heparin and reintroduction of bovine heparin by FDA are also covered. To calculate the global heparin market size, the report considers revenue generated from the sales of generic and branded therapeutic products, including Unfractionated heparin (UFH), Low molecular weight heparin (LMWH) and Ultra low molecular weight heparin (ULMWH).
Regionally, another research titled China Heparin Industry Report, 2014-2017 says in terms of the proposed/ongoing projects, it is projected that the heparin API in China will achieve an additional capacity of more than 20 trillion units by 2015, when China’s total capacity will exceed 30 trillion units, accounting for roughly 80% of the global demand. Given that America’s economy shows signs of recovery and the European economy does not continue to deteriorate, this research forecasts that the market size of the global heparin API and preparation market will bounce back in 2014-2017, when China’s heparin industry, heparin API in particular, will see an improved degree of prosperity, thus further releasing new capacity. The major global heparin API suppliers, including Hepalink, Nanjing King-friend, Dongcheng Biochemicals, Qianhong Bio-pharma, and Changshan Biochemical Pharmaceutical, have been among the top 4 heparin exporters in China for many years, together accounting for over 60% of China’s total heparin exports. In response to the impact from international markets, enterprises are stepping up efforts to figure out the solutions, with Hepalink expanding its market share of heparin crude products via M&As overseas. By contrast, the enterprises like Qianhong Bio-pharma, Dongcheng Biochemicals, and Changshan Biochemical Pharmaceutical have accelerated the R&D into and production of low molecular weight heparin preparations. And Nanjing King-friend is aggressively seeking to expand capacity through IPO. Companies profiled in this China heparin market report along with their data and information on one or all of the following points – Operation, Revenue Structure, Gross Margin, R&D and Investment, Major Clients, Heparin Business as well as Prospect and Forecast – include Hepalink, Qianhong Bio-pharma, Dongcheng Biochemicals, Changshan Biochemical Pharmaceutical, Tianjin Chase Sun Pharmaceutical, Nanjing King-friend and Wanbang Biopharmaceuticals. This research is supported with 104 charts to help understand the Chinese heparin market analysis. Order a copy of China Heparin Industry Report, 2014-2017 at http://www.reportsnreports.com/Purchase.aspx?name=312048 .
A third research titled Future Horizons and Growth Strategies in the Heparin Testing Market 2014: Country Forecasts presents a detailed analysis of the Heparin testing market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan, including clinical significance and current laboratory practice, as well as 5- and 10-year test volume forecasts by country and market segment. The report examines market applications of chromogenic substrates, monoclonal antibodies, immunoassays, IT, DNA probes, biochips/microarrays, and other technologies; reviews features and operating characteristics of automated analyzers; profiles leading suppliers and recent market entrants developing innovative technologies and products; and identifies alternative market penetration strategies and entry barriers/risks. Read more at http://www.reportsnreports.com/reports/296455-future-horizons-and-growth-strategies-in-the-heparin-testing-market-2014-country-forecasts.html .
Explore more reports on the pharmaceuticals market at http://www.reportsnreports.com/market-research/pharmaceuticals/ .
ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.
Connect With Us on:
Twitter: https: //twitter.com/marketsreports
G+ / Google Plus: https://plus.google.com/111656568937629536321/posts
RSS/Feeds: http: //http://www.reportsnreports.com/feed/l-latestreports.xml
TX, Dallas North – Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
Back to top
market news – Bing News